Sapphire 3 CTO Study

A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 170 participants.

Also called NCT06358508

  • Study
  • In this atlas

Overview

Design
Interventional study; allocation not applicable; no masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 170 participants (enrolled count) (from the registry)
Sponsor
  • Avania Registry lists this organization as a collaborator
  • OrbusNeich Registry lists this organization as the lead sponsor
Registry
  • NCT NCT06358508
Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Spain (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT06358508. Allocation not applicable; no masking; primary purpose treatment. Start 2024-11-06 (actual); primary completion 2025-10-21 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Sapphire 3 CTO Study
Condition
Coronary Disease
Condition
Myocardial Ischemia
Condition
Heart Diseases
Condition
Arteriosclerosis
Condition
Cardiovascular Diseases
Condition
Chronic Total Occlusion
Condition
Chronic Total Occlusion of Coronary Artery
Intervention (Device)
Sapphire 3 Coronary Dilatation Catheter
Lead sponsor
OrbusNeich (class: industry)
Collaborator
Avania (class: industry)

Record details

Record id
cardio:ct-nct06358508
Content hash
5da901c809f494e156547c56c267cd43aa4dbdeb0be8e3701a7648c0a98f2315